EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Half Year Results/Half Year Results IGEA DISCLOSES ITS HALF-2021 FINANCIALS Hoofddorp, the Netherlands, 30September 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its half-2021 financials. Highlights The EBITDA as adjusted (before impairment charge) and EBIT figures amount to TUSD -264.3 (previous period: TUSD -481.6) and TUSD -291.3 (previous period: -544.6) respectively. The change compared to the previous period is mainly due to the recognition of fair value gains on financial liabilities at fair value through profit or loss for TUSD 245.2 and gains from the sale of certain tangible assets for TUSD 64.5, both presented as 'other gains' in the statement of profit or loss. The net loss for the period is TUSD 291.5 (previous period: TUSD 547.3), representing a basic and diluted loss per share of USD 0.012 and USD 0.011 respectively (previous period: basic and diluted loss per share of USD 0.022). As of 30 June 2021, the Group held non-current assets for TUSD 387.3 and current assets for TUSD 168.7 (31 December 2020: TUSD 441.6 and TUSD 289.5 respectively), with no changes due to relevant events;The Group's current liabilities were TUSD 733.2 (31 December 2020: TUSD 24.4 and TUSD 522.2 of non-current and current liabilities respectively), the overall increase in current liabilities mainly due to financial debts in the form of loans, CARES Act (US) based loans and liabilities in the form of derivative financial instruments related to the Negma transaction. The cash flow did not materially change in respect of the previous period. Funds to operate were granted by way of debt transactions. Negma's commitment grants the cash and cash equivalents necessary to finance the combined Group's level of activities for at least twelve months. The half year financial report 2021 is available at https://www.igeapharma.nl/category/financial-reports/ About IGEA IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl Disclaimer End of ad hoc announcement |
Language: | English |
Company: | IGEA Pharma N.V. |
Siriusdreef 17 | |
2123 WT Hoofddorp | |
Netherlands | |
Phone: | +31 23 568 9494 |
E-mail: | info@igearesearch.com |
Internet: | www.igeapharma.nl |
ISIN: | NL0012768675 |
Listed: | Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange |
EQS News ID: | 1237390 |
End of Announcement | EQS Group News Service |
1237390 30-Sep-2021 CET/CEST